Thrombocytosis in Pneumonia Patients: A Marker of Severe Inflammation and Variable Mortality Risk - Takeaways - MDSpire

Thrombocytosis in Pneumonia Patients: A Marker of Severe Inflammation and Variable Mortality Risk

  • By

  • Cheng Liu

  • Lili He

  • Yuanhao Guo

  • Yang Su

  • Yao Wei

  • Yongxin Li

  • Xiaolong Ma

  • Rui Qiao

  • February 24, 2026

  • 0 min

Share

  • 1

    Platelets play a significant role in inflammation and immune response, particularly in pneumonia patients post-COVID-19.

  • 2

    This study analyzed 2754 pneumonia patients to assess the prognostic significance of reactive thrombocytosis on mortality.

  • 3

    Reactive thrombocytosis was defined as a platelet count ≥ 400 × 10⁹/L, while thrombocytopenia was defined as < 90 × 10⁹/L.

  • 4

    The primary outcome measured was in-hospital mortality, with secondary outcomes including length of stay and 30-day mortality.

  • 5

    Statistical analyses included Cox regression and ROC curves to evaluate the relationship between platelet levels and mortality risk.

Original Source(s)

Thrombocytosis in Pneumonia Patients: A Marker of Severe Inflammation and Variable Mortality Risk

  • by Cheng Liu, Lili He, Yuanhao Guo, Yang Su, Yao Wei, Yongxin Li, Xiaolong Ma, Rui Qiao

  • February 24, 2026

Related Content

Correction: Recovery from Chlamydia psittaci Pneumonia Presenting Without Cough - A Case Study and Review of Existing Literature

Postextubation Pneumonia Tops Ventilator Pneumonia

Older age, male sex, underweight status, reduced activities of daily living, and mild consciousness disturbance were associated with postextubation pneumonia in elective surgical patients.

The 18-Month MDR-TB Regimen Has a Successor

Six months, all-oral, better tolerated—and the infrastructure to make it work.